4Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627-36.
二级参考文献23
1 Scheen AJ. Drugtreatment of NIDDM in the 1990s[J].Drugs, 1997,54(3)∶355
2 Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia[J].Drugs,1999,57(1)∶19 [3] Langtry HD, Balfour JA. Glimepiride: A review of its use in the management oftype 2 diabetes mellitus[J].Drugs, 1998,55(4)∶563
3 Graul A, Castaner J. Repaglinide[J].Drugs Future,1996,21(7)∶694
4Scrip,1999,(2451)∶30
5 Deacon CF, Holst JJ, Carr RD. Glucagon-like peptide-1: A basis for newapproaches to the management of diabetes[J].Drugs Today, 1999,35(3)∶159
6 Plosker GL, Fauld D. Troglitazone: A review of its use in the management oftype 2 diabetes mellitus[J].Drugs,1999,57(3)∶409